Association between frailty and the risk of all-cause and cause-specific mortality among cancer patients

Author:

Zhai Chongya1,Yin Luxi2,Shen Jiaying2,Dong Jie1,Zheng Yu1,Pan Hongming2,Han Weidong2

Affiliation:

1. Sir Run Run Shaw Hospital

2. Zhejiang University

Abstract

Abstract Background Cancer patients are vulnerable to frailty. While few studies have focused on its association with the mortality risk among cancer patients, the current study aims to reveal this association. Methods In this cohort study, 4723 cancer patients were enrolled from the National Health and Nutrition Examination Surveys (NHANES, 1999–2018). Frailty status was quantified using the 53-item frailty index. Death outcomes were linked to National Death Index Mortality data (as of December 31, 2019). Cox proportional hazard models were used to estimate HR (95% CI). Results The median (IQR) of the frailty score was 0.190 (0.132, 0.277). During the median follow-up of 6.7 years, 1775 all-cause deaths (including 581 cancer deaths and 385 cardiac deaths) were documented. Compared to the lowest tertile of frailty score, the adjusted HRs (95% CIs) for the highest tertile were 2.698 (2.224, 3.272) in all-cause mortality (P trend < 0.001), 2.145 (1.547, 2.973) in cancer mortality (P trend < 0.001), and 3.735 (2.231, 6.251) in cardiac mortality (P trend < 0.001). Moreover, a positive dose-response association between frailty score and mortality risk was determined. Per-unit increment of frailty score (natural logarithm transformed) was found to increase all-cause mortality by 159% (P < 0.001), cancer mortality by 103% (P < 0.001), and cardiac mortality by 256% (P < 0.001). The consistent result was shown when stratifying by age, gender, race, body mass index, and type of cancer. Conclusion This study suggested that the frailty index was positively associated with all-cause mortality and cause-specific mortality (including cancer and cardiac) among cancer patients.

Publisher

Research Square Platform LLC

Reference41 articles.

1. Yang, J., X. Li, and D. Xu, Research Progress on the Involvement of ANGPTL4 and Loss-of-Function Variants in Lipid Metabolism and Coronary Heart Disease: Is the "Prime Time" of ANGPTL4-Targeted Therapy for Coronary Heart Disease Approaching? Cardiovascular drugs and therapy, 2020.

2. Organization, W.H., Global Health Observatory. Geneva. http://www.who.int/data/gho. Accessed: Dec 2020.

3. Kopin, L. and C. Lowenstein, Dyslipidemia. Ann Intern Med, 2017. 167(11): p. ITC81-ITC96.

4. Medical costs and productivity losses of cancer survivors–United States, 2008–2011;Ekwueme DU;MMWR Morb Mortal Wkly Rep,2014

5. Measuring Aging and Identifying Aging Phenotypes in Cancer Survivors;Guida JL;J Natl Cancer Inst,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3